Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
N Engl J Med
    April 2024
  1. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    N Engl J Med. 2024;390:1163-1175.
    >> Share

    March 2024
  2. SLAMON D, Lipatov O, Nowecki Z, McAndrew N, et al
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:1080-1091.
    >> Share

    November 2023
  3. WHELAN TJ, Parpia S, Levine MN
    Omitting Radiotherapy in Luminal A Breast Cancer. Reply.
    N Engl J Med. 2023;389:1727-1728.
    >> Share

  4. RECHT A
    Omitting Radiotherapy in Luminal A Breast Cancer.
    N Engl J Med. 2023;389:1727.
    >> Share

    August 2023
  5. WHELAN TJ, Smith S, Parpia S, Fyles AW, et al
    Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer.
    N Engl J Med. 2023;389:612-619.
    >> Share

    June 2023
  6. TURNER NC, Oliveira M, Howell SJ, Dalenc F, et al
    Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
    N Engl J Med. 2023;388:2058-2070.
    >> Share

    May 2023
  7. GIORDANO SH
    POSITIVE Results for Breast Cancer Survivors Who Desire Pregnancy.
    N Engl J Med. 2023;388:1709-1710.
    >> Share

  8. PARTRIDGE AH, Niman SM, Ruggeri M, Peccatori FA, et al
    Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
    N Engl J Med. 2023;388:1645-1656.
    >> Share

    March 2023
  9. AKHAM R, Hazarika N
    Paget's Disease of the Breast.
    N Engl J Med. 2023;388:1126.
    >> Share

  10. CALLISON K, Pesko MF, Phillips S, Sosa JA, et al
    Cancer Screening after the Adoption of Paid-Sick-Leave Mandates.
    N Engl J Med. 2023;388:824-832.
    >> Share

    February 2023
  11. HO AY, Bellon JR
    Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer.
    N Engl J Med. 2023;388:652-653.
    >> Share

  12. KUNKLER IH, Williams LJ, Jack WJL, Cameron DA, et al
    Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.
    N Engl J Med. 2023;388:585-594.
    >> Share

    October 2022
  13. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    >> Share

  14. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    >> Share

  15. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    >> Share

    September 2022
  16. MODI S, Gambhire D, Cameron D
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
    N Engl J Med. 2022;387:1145-1146.
    >> Share

  17. CARROLL HK, Higgins MJ, O'Reilly S
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1144.
    >> Share

  18. SCHNOG JB, Samson MJ, Duits AJ
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1143-1144.
    >> Share

    August 2022
  19. CHRISTIAN NT, Borges VF
    What Dobbs Means for Patients with Breast Cancer.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
    >> Share

    July 2022
  20. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    >> Share

  21. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    >> Share

  22. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    >> Share

    June 2022
  23. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    >> Share

  24. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    >> Share

  25. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    >> Share

  26. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    >> Share

    May 2022
  27. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    >> Share

  28. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    >> Share

    March 2022
  29. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    >> Share

  30. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    >> Share

    February 2022
  31. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    >> Share

    December 2021
  32. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    >> Share

  33. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    >> Share

    October 2021
  34. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    >> Share

  35. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    >> Share

  36. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    >> Share

    September 2021
  37. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016